1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH. This program encourages applications to plan multi-center clinical studies.
While not specific to bioartificial kidneys, research planning for such complex medical devices would fall under clinical study implementation.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) - PAR-25-090 - NIDDK NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34).
The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the clinical study.
The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).
Funding Opportunity Details Related Notices or Announcements: Tracy Rankin, Ph. D. , M.
P. H. ; Barbara Linder, M.
D. , Ph. D.
; Aynur Unalp-Arida, M. D. , Ph.
D. U34 - Multi-Center Clinical Study Cooperative Agreement Letter of Intent Due Date:
According to the current listing, eligibility includes: Institutions/organizations capable of planning multi-center clinical studies. Specific details would be in the full announcement. Confirm the full requirements in the official notice before applying.
NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) is funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs from NIDDK are competitive federal grant programs administered by the National Institute of Diabetes and Digestive and Kidney Diseases supporting innovative research by small businesses with potential for commercialization. NIDDK participates in both SBIR and STTR programs, with funding opportunities aligned to its mission areas in diabetes, digestive diseases, and kidney diseases. Eligible applicants are U.S. small businesses with innovative research applicable to NIDDK's scientific program areas. The NIH SEED website provides comprehensive application guidance and NIDDK-specific program contacts.
NIDDK High Risk, High Impact Research is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH. NIDDK supports high-risk, high-impact research to advance understanding and treatment of kidney diseases. Development of a bioartificial kidney would be considered high-impact research. This would likely be pursued through general NIH funding mechanisms (e.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article